Accueil   Diary - News   All news BIOCORP and NOVO NORDISK sign global partnership within diabetes on digital health

BIOCORP and NOVO NORDISK sign global partnership within diabetes on digital health

 

 

  • Biocorp and Novo Nordisk partner in the smart pen area, Biocorp leveraging Mallya platform for the Novo Nordisk prefilled pen platform

 

  • Mallya smart add-on device will attach directly to disposable pre-filled FlexTouch® pens. Aiming to help people with diabetes to have more personalised consultations with their HCPs, the device will allow dose logging.

 

  • Financial participation of Novo Nordisk in the development plan of Biocorp.

 

Issoire (France) September 27th, 2021, at 6:45 am CEST – BIOCORP (FR0012788065 – ALCOR / Eligible PEA PME), a French company specialized in the design, development, and manufacturing of innovative medical devices, today announces an agreement with Novo Nordisk, a world leader in diabetes care, for the development and distribution (pending successful development) of a Mallya smart add-on device for the Novo Nordisk FlexTouch pen used by people with diabetes.

 

 

Read the press release